OIL.AU Optiscan Imaging Ltd
- Market cap
- AUD 162M
- P/E
- -
- P/B
- 8.55x
- ROE
- -36.9%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is OIL.AU undervalued?
Graham numberThe Graham number of Optiscan Imaging Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Optiscan Imaging Ltd fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-36.9%), below 10%.
ROA 1/1
Return on assets (-31.7%) is above the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (7.2%) is below the industry median (24.9%).
Revenue Growth 0/2
Revenue shrank 35.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (7.1%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 2.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (8.6x) is above the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Optiscan Imaging Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Optiscan Imaging Ltd
Optiscan Imaging Limited engages in the development, manufacture, and commercialisation of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications in Germany and the United States. It offers InVue, a microscopic medical imaging device for precision surgery; InForm, a digital pathology imaging device for pathology workflows; InVivage, an intra-oral endomicroscope for oral imaging solutions; and ViewnVivo, a miniaturized i…
Full company profileOptiscan Imaging Ltd financial statements
Optiscan Imaging Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.33M | 2.97M | 1.32M | 1.19M | 890K | 1.01M | 1.68M | 1.16M | 3.72M | 449K |
| Gross Profit | 827K | 1.72M | 216K | 550K | -386K | -1.66M | 515K | 629K | 3.25M | -790K |
| Operating Income | -3.88M | -2.00M | -2.35M | -2.38M | -3.72M | -5.47M | -5.29M | -8.41M | -6.17M | -10.6M |
| EBITDA | -3.84M | -1.92M | -2.45M | -1.46M | -2.68M | -3.96M | -4.68M | -6.46M | -6.17M | -10.3M |
| Net Income | -2.94M | -2.04M | -2.34M | -1.77M | -2.13M | -4.23M | -4.35M | -6.06M | -6.31M | -6.99M |
| EPS | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 2.67M | 4.13M | 3.64M | 3.44M | 11.7M | 7.98M | 4.67M | 15.6M | 10.6M | 22.0M |
| Total Liabilities | 1.00M | 929K | 821K | 1.90M | 1.48M | 1.39M | 1.63M | 1.76M | 2.84M | 3.08M |
| Shareholders' Equity | 1.67M | 3.20M | 2.82M | 1.55M | 10.2M | 6.59M | 3.04M | 13.9M | 7.71M | 18.9M |
| Cash & Short-term Investments | 701K | 1.56M | 1.75M | 526K | 8.44M | 4.53M | 875K | 11.2M | 4.55M | 14.4M |
| Total Debt | - | - | 200K | 1.16M | 668K | 571K | 412K | 221K | 1.48M | 1.34M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.41M | -2.32M | -1.42M | -1.40M | -2.13M | -3.83M | -3.15M | -5.74M | -6.21M | -7.10M |
| Capital Expenditure | 181K | 291K | 4.51K | 20.2K | 30.9K | 124K | 127K | 87.4K | 93.1K | 256K |
| Free Cash Flow | -3.59M | -2.61M | -1.43M | -1.42M | -2.16M | -3.96M | -3.28M | -5.83M | -6.31M | -7.36M |
| Ratios | ||||||||||
| ROE | -176.7% | -63.6% | -83.0% | -114.0% | -20.8% | -64.2% | -142.9% | -43.7% | -81.8% | -36.9% |
| ROA | -110.4% | -49.3% | -64.3% | -51.2% | -18.2% | -53.0% | -93.1% | -38.8% | -59.8% | -31.7% |
| Net Profit Margin | -220.7% | -68.6% | -177.3% | -148.3% | -239.1% | -417.9% | -259.0% | -524.4% | -169.5% | -1,556.7% |
| Debt to Equity | - | - | 0.07x | 0.75x | 0.07x | 0.09x | 0.14x | 0.02x | 0.19x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Optiscan Imaging Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | AUD 156K | 0.00 | - |
| 2021 | AUD 9.82M | 0.02 | - |
| 2020 | AUD 351K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | AUD 3.02M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 440:437 on Sep 1, 2025.
Who owns Optiscan Imaging Ltd
- Insiders 48.58%
- Institutions 14.83%
- Public & others 36.59%
- Shares outstanding 1.05B
- Free float 398M
Optiscan Imaging Ltd company profile
- Company name
- Optiscan Imaging Ltd
- Ticker
- OIL.AU
- ISIN
- AU000000OIL4
- Exchange
- Australian Securities Exchange
- Sector
- Technology
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- 16 Miles Street, Mulgrave, VIC, Australia, 3170
- Phone
- 61 3 9538 3333
- Website
- optiscan.com
About Optiscan Imaging Ltd
Optiscan Imaging Limited engages in the development, manufacture, and commercialisation of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications in Germany and the United States. It offers InVue, a microscopic medical imaging device for precision surgery; InForm, a digital pathology imaging device for pathology workflows; InVivage, an intra-oral endomicroscope for oral imaging solutions; and ViewnVivo, a miniaturized in vivo imaging device for life sciences, pre-clinical and translational research. The company also provides InSpecta, a novel digital microscopic imaging device for veterinary medicine. Optiscan Imaging Limited was founded in 1994 and is headquartered in Mulgrave, Australia.
Optiscan Imaging Ltd management
4- Dr. Camile Farah M.A.I.C.D., M.B.A., Ph.D.CEO, MD & Executive Director
- Mr. Darius OoiChief Financial Officer
- Dr. Sanchitha FernandoChief Technology Officer
- Kaylene DawsonGeneral Counsel